Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

BACKGROUND: Non-small cell lung cancer is the most common cause of cancer death worldwide, highlighting the need for novel therapeutic concepts. In particular, there is still a lack of treatment strategies for the group of elderly and frail patients, who are frequently not capable of receiving stand...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Bozorgmehr, Farastuk, Chung, Inn, Christopoulos, Petros, Krisam, Johannes, Schneider, Marc A., Brückner, Lena, Mueller, Daniel Wilhelm, Thomas, Michael, Rieken, Stefan
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Study Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7447611/
https://ncbi.nlm.nih.gov/pubmed/32842974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07264-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars